# US 2012/0231482 A1 · Method, kit or diagnostic for the detection of reagents which induce altered contractility

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0231482 A1
- Document ID: US20120231482A1
- Status: Published application
- Kind: A1
- Application number: 13/509,397
- Filed: 2010-11-15
- Published: 2012-09-13
- Earliest claimed: 2009-11-13
- Assignees: The Johns Hopkins University
- Inventors: Christopher I. Murray; Jennifer E. Van Eyk; Nazareno Paolocci; Wei Dong Gao; Darren Brian Foster
- Web page: https://patentgrep.com/patent/US20120231482A1

## CPC

- G01N 33/5061: {Muscle cells}
- G01N 33/6887: {from muscle, cartilage or connective tissue}
- G01N 2333/4712: Muscle proteins, e.g. myosin, actin, protein
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of screening for compounds that enhance or depress contractile function, based on measuring the formation of heterodimers of contractile fibers (e.g. Tm and actin, myosin heavy and myosin light chains), for example through disulfide bond formation. Diagnostic and prognostic methods and kits are also provided.

## Claims

### Claim 1

A method for screening for an agent that increases contractility in a contractile cell comprising the steps of:
a. contracting a test agent with a composition comprising contractile proteins from said cell; and
b. measuring the formation of at least one cross link to form a heterodimer between said contractile proteins,
wherein the formation of at least one cross link between said proteins is indicative of an potential agent for increasing contractility of said cell.

### Claim 2 (depends on 1)

The method of claim 1 wherein the contractile cell is a muscle cell.

### Claim 3 (depends on 2)

The method of claim 2 wherein the muscle cell is a smooth muscle cell, a skeletal muscle cell or a cardiac muscle cell.

### Claim 4 (depends on 1)

The method of claim 1 wherein the contractile cell is a cell having motility.

### Claim 5 (depends on 4)

The method of claim 4 wherein the cell is a blood cell.

### Claim 6 (depends on 1)

The method of claim 1 wherein the contractile proteins are tropomyosin (TM) and actin, myosin heavy and myosin light chains.

### Claim 7 (depends on 1)

The method of claim 1 wherein the link is a disulfide bond.

### Claim 8 (depends on 7)

The method of claim 7 wherein the link is formed between Cysteine residue 190 of TM and Cys 257 of actin, or between Cys 37 of myosin heavy chain and Cys 81 of myosin light chain 1.

### Claim 9 (depends on 1)

The method of claim 1 wherein cross-linkage is measured by a method selected from the group consisting of molecular weight assay, antibody assay, molecular sieving assay, and mass spectrometry.

### Claim 10

A method for screening for an agent that reduces contractility in a contractile cell comprising the steps of:
a. contracting a test agent with a composition comprising contractile proteins from said cell in heterodimer form; and
b. measuring the disruption of at least one cross link between said contractile proteins; wherein the disruption of at least one cross link between said proteins is indicative of a potential agent for decreasing contractility of said cell.

### Claim 11 (depends on 10)

The method of claim 10 wherein the contractile cell is a muscle cell.

### Claim 12 (depends on 11)

The method of claim 11 wherein the muscle cell is a smooth muscle cell, a skeletal muscle cell or a cardiac muscle cell.

### Claim 13 (depends on 10)

The method of claim 10 wherein the contractile proteins are selected from TM and actin, and myosin heavy and myosin light chains.

### Claim 14 (depends on 10)

The method of claim 10 wherein the link is a disulfide bond.

### Claim 15 (depends on 14)

The method of claim 14 wherein the link is formed between Cysteine residue 190 of TM and Cys 257 of actin, or between Cys 37 of myosin heavy chain and Cys 81 of myosin light chain 1.

### Claim 16 (depends on 10)

The method of claim 10 wherein cross-linkage is measured by a method selected from the group consisting of molecular weight assay, antibody assay, molecular sieving assay, and mass spectrometry.

### Claim 17

A diagnostic method comprising the step of detecting and/or measuring the level of a heterodimer comprised of contractile proteins in a biological sample wherein the presence and/or level of said heterodimer is correlated with a diagnosis, prognosis or treatment outcome.

### Claim 18 (depends on 17)

The method of claim 17 wherein the diagnosis, prognosis or treatment outcome is for a cardiac disease or disorder.

### Claim 19 (depends on 18)

The method of claim 18 wherein the cardiac disease or disorder is heart failure or myocardial stunning.

### Claim 20 (depends on 17)

The method of claim 17 wherein the diagnosis, prognosis or treatment outcome is for a disease or disorder of skeletal muscle.

### Claim 21 (depends on 20)

The method of claim 20 wherein the disease or disorder of skeletal muscle is muscle cramping.

### Claim 22 (depends on 17)

The method of claim 17 wherein the diagnosis, prognosis or treatment outcome is for a disease or disorder of smooth muscle.

### Claim 23 (depends on 22)

The method of claim 22 wherein the disease or disorder of smooth muscle is selected from the group consisting of irritable bowl and gastric mobility, asthma, vascular spasm, uterine contraction involved in premature delivery of delivery itself, and menstrual cramps.

### Claim 24 (depends on 17)

The method of claim 17 wherein the diagnosis, prognosis or treatment outcome is for a cancer.

### Claim 25 (depends on 17)

The method of claim 17 wherein the biological sample is a blood sample, a tissue biopsy or a bodily fluid.

### Claim 26 (depends on 25)

The method of claim 25 wherein the biological sample is a serum or plasma sample.

### Claim 27

A kit for screening for an agent that modifies cellular contractility, said kit comprising at least one antibody directed to a contractile protein, a denaturing gel, and a control sample comprising a contractile protein in homodimeric form.

### Claim 28 (depends on 27)

The kit of claim 27, additionally comprising a nitrocellulose membrane.

### Claim 29 (depends on 27)

The kit of claim 27, additionally comprising at least one digestive enzyme.

### Claim 30 (depends on 29)

The kit of claim 29, wherein the digestive enzyme is trypsin or chymotrypsin.

### Claim 31

An isolated biomarker comprising a heterodimer comprised of contractile proteins, wherein the presence of said biomarker in a biological sample is indicative of altered contractility of a contractile cell.

### Claim 32

An isolated biomarker consisting of cross-linked contractile proteins having a molecular weight which indicate the presence of a heterodimer.
